In vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas

Translational Oncology

Volumn 6, Issue 2, 2013, Pages 187-196

  Martinho, Olga ^a,b,c   Silva Oliveira, Renato ^c   Miranda Gonçalves, Vera ^a,b   Clara, Carlos ^c   Almeida, José Reynaldo ^d   Carvalho, André Lopes ^c   Barata, João Taborda ^d   Reis, Rui Manuel ^a,b,c  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c BARRETOS CANCER HOSPITAL   (Brazil)

^d UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84875783182     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12400     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61(2), 69-90.
2. Wen PY and Kesari S (2008). Malignant gliomas in adults. N Engl J Med 359, 492-507.
3. Huse JT and Holland EC (2010). Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10, 319-331.
4. Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, and Belka C (2011). Therapeutic options for recurrent malignant glioma. Radiother Oncol 98, 1-14.
5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
6. Kapoor GS and O'Rourke DM (2003). Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches. Cancer Biol Ther 2, 330-342.
7. Gomes AL, Reis-Filho JS, Lopes JM, Martinho O, Lambros MB, Martins A, Schmitt F, Pardal F, and Reis RM (2007). Molecular alterations of KIT oncogene in gliomas. Cell Oncol 29, 399-408.
8. Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, Pardal F, Amorim J, Mackay A, Milanezi F, et al. (2009). Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer 101, 973-982.
9. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
10. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, et al. (2011). Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20(6), 810-817.
11. Little SE, Popov S, Jury A, Bax DA, Doey L, Al-Sarraj S, Jurgensmeier JM, and Jones C (2012). Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res 72, 1614-1620.
12. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, et al. (2012). Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 109, 3041-3046.
13. Tuettenberg J, Friedel C, and Vajkoczy P (2006). Angiogenesis in malignant glioma-a target for antitumor therapy? Crit Rev Oncol Hematol 59, 181-193.
14. Norden AD, Drappatz J, and Wen PY (2008). Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7, 1152-1160.
15. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, and Talpaz M (2001). Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344, 1038-1042.
16. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347, 472-480.
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356, 115-124.
18. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390.
19. Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, et al. (2009). A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer 45, 2352-2359.
20. Wen PY, Yung WKA, Lamborn KR, Dahia PL, Wang YF, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, et al. (2006). Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12, 4899-4907.
21. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al. (2009). Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27, 740-745.
22. Wong ET, Gautam S, Malchow C, Lun M, Pan E, and Brem S (2011). Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 9, 403-407.
23. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, et al. (2011). Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108, 3749-3754.
24. De Witt Hamer PC (2010). Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 12, 304-316.
25. Papaetis GS and Syrigos KN (2009). Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23, 377-389.
26. Navis AC, Hamans BC, Claes A, Heerschap A, Jeuken JW, Wesseling P, and Leenders WP (2011). Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. J Pathol 223, 626-634.
27. Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, et al. (2010). MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 12, 822-833.
28. de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, and Guillamo JS (2007). Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9, 412-423.
29. Zhou Q, Guo P, and Gallo JM (2008). Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 14, 1540-1549.
30. MendelDB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9, 327-337.
31. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, and Hallahan DE (2003). SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63, 4009-4016.
32. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, et al. (2010). Phase II study of sunitinib malate in patientswith recurrent high-grade glioma. J Neurooncol 103(3), 491-501.
33. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, et al. (2005). AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65, 4389-4400.
34. Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, et al. (2011). Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther 10, 861-873.
35. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, et al. (2010). Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28, 2817-2823.
36. Batchelor TT, Duda DG, Di Tomaso E, Kozak KR, Zhang W, Ancukiewicz M, Loeffler JS, Wen PY, Sorensen GA, and Jain RK (2007). Normalization of tumor vasculature and alleviation of edema by AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor in glioblastoma patients. Int J Radiat Oncol Biol Phys 69, S50-S51.
37. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95.
38. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, et al. (2009). Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27, 2542-2552.
39. Martinho O, Granja S, Jaraquemada T, Caeiro C, Miranda-Goncalves V, Honavar M, Costa P, Damasceno M, Rosner MR, Lopes JM, et al. (2012). Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. PLoS One 7, e30769.
40. Silva-Correia J, Miranda-Goncalves V, Salgado AJ, Sousa N, Oliveira JM, Reis RM, and Reis RL (2012). Angiogenic potential of Gellan-gum-based hydrogels for application in nucleus pulposus regeneration: in vivo study. Tissue Eng Part A 18(11-12), 1203-1212.
41. Moniz S, Martinho O, Pinto F, Sousa B, Loureiro C, Oliveira MJ, Moita LF, Honavar M, Pinheiro C, Pires M, et al. (2013). Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. Hum Mol Genet 22(1), 84-95.
42. Hagerstrand D, Hesselager G, Achterberg S, Wickenberg BU, Kowanetz M, Kastemar M, Heldin CH, Isaksson A, Nister M, and Ostman A (2006). Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25, 4913-4922.
43. Shingu T, Fujiwara K, Bogler O, Akiyama Y, Moritake K, Shinojima N, Tamada Y, Yokoyama T, and Kondo S (2009). Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. Int J Cancer 124, 1060-1071.
44. Ranza E, Mazzini G, Facoetti A, and Nano R (2010). In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neurooncol 96, 349-357.
45. Gross D, Bernhardt G, and Buschauer A (2006). Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity. J Cancer Res Clin Oncol 132, 589-599.
46. Dimitropoulos K, Giannopoulou E, Argyriou AA, Zolota V, Petsas T, Tsiata E, and Kalofonos HP (2010). The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins. Anticancer Res 30, 4987-4992.
47. Giannopoulou E, Dimitropoulos K, Argyriou AA, Koutras AK, Dimitrakopoulos F, and Kalofonos HP (2010). An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. Invest New Drugs 28, 554-560.
48. Wachsberger PR, Lawrence RY, Liu Y, Xia X, Andersen B, and Dicker AP (2011). Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. J Neurooncol 105(2), 181-190.
49. Wachsberger PR, Lawrence YR, Liu Y, Daroczi B, Xu X, and Dicker AP (2010). Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. Int J Radiat Oncol Biol Phys 82(1), 483-491.
50. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, et al. (2011). Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 71, 19-28.
51. Hoelzinger DB, Demuth T, and Berens ME (2007). Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99, 1583-1593.
52. Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N, and Yang B (2009). Differential effect of imatinib and synergismof combination treatment with chemotherapeutic agents in malignant glioma cells. Basic Clin Pharmacol Toxicol 104, 241-252.
53. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290.
54. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, LindemanN, Gale CM, Zhao X, Christensen J, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
55. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, DellaCK, Wisner L, Iorio M, Shakalya K, Garewal H, et al. (2007). A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26, 3909-3919.